Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data

Spyre Therapeutics said Tuesday it is deprioritizing its antibody candidate for rheumatoid arthritis (RA) after the drug missed the biotech’s bar for success in a mid-stage trial. The results also put a dampener on the ...